GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GENELUX Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.45+0.03 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $110.15M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
21.7%
10M of 45M shares
Institutional holders
72
11 new, 10 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 25 sales
Net sold $368.19K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 4,223,277 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Aladar Szalay | 3,134,286 | 8.20% | 13G (passive) amendment | Dec 31, 2025 |
| Highbridge Capital Management, LLC | 2,500,000 | 6.80% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GNLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 2,262,108 | 5.00% | $6.81M | +144,925 | 3.00% |
| Vanguard Capital Management LLC | 1,677,724 | 3.71% | $5.05M | −17,756 | 0.00% |
| Bleichroeder LP | 1,380,666 | 3.05% | $4.16M | – | 0.74% |
| BlackRock, Inc. | 439,602 | 0.97% | $1.32M | +33,730 | 0.00% |
| Geode Capital Management, LLC | 439,213 | 0.97% | $1.32M | −14,548 | 0.00% |
| CM Management, LLC | 400,000 | 0.88% | $1.20M | +150,000 | 0.80% |
| Bank Of America Corp /De/ | 328,803 | 0.73% | $989.70K | +4,938 | 0.00% |
| Vanguard Fiduciary Trust Co | 236,344 | 0.52% | $711.40K | −15,266 | 0.00% |
| Flputnam Investment Management Co | 231,405 | 0.51% | $696.53K | −49,499 | 0.01% |
| Global Retirement Partners, LLC | 227,854 | 0.50% | $685.84K | New | 0.01% |
| LPL Financial LLC | 157,857 | 0.35% | $475.15K | +18,816 | 0.00% |
| State Street Corp | 145,850 | 0.32% | $439.01K | – | 0.00% |
| Provident Wealth Management, LLC | 144,908 | 0.32% | $436.17K | −10,762 | 0.11% |
| LifeSteps Financial, Inc. | 121,965 | 0.27% | $367.12K | +3,103 | 0.17% |
| Osaic Holdings, Inc. | 121,958 | 0.27% | $367.09K | +2,950 | 0.00% |
| Renaissance Technologies LLC | 105,229 | 0.23% | $316.74K | +93,029 | 0.00% |
| Northern Trust Corp | 89,279 | 0.20% | $268.73K | −75,177 | 0.00% |
| Citadel Advisors LLC | 85,481 | 0.19% | $257.30K | New | 0.00% |
| Morgan Stanley | 83,543 | 0.18% | $251.46K | −4,505 | 0.00% |
| SteelPeak Wealth, LLC | 75,895 | 0.17% | $228.44K | +15,000 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 10M | 21.7% | 11 / 19 | 15 / 10 | 1M | 1M |
| Q1 2026 | 71 | 9M | 20.6% | 12 / 16 | 14 / 17 | 3M | 1M |
| Q4 2025 | 78 | 9M | 20.2% | 22 / 20 | 12 / 1 | 2M | 0M |
| Q3 2025 | 57 | 7M | 16.5% | 6 / 21 | 5 / 10 | 1M | 1M |
| Q2 2025 | 61 | 7M | 16.3% | 7 / 19 | 11 / 21 | 1M | 1M |
| Q1 2025 | 75 | 7M | 16.1% | 26 / 21 | 12 / 8 | 3M | 0M |
| Q4 2024 | 58 | 5M | 10.8% | 9 / 11 | 20 / 7 | 1M | 1M |
| Q3 2024 | 57 | 5M | 11.6% | 5 / 17 | 17 / 20 | 1M | 2M |
| Q2 2024 | 73 | 7M | 15.7% | 26 / 15 | 20 / 20 | 3M | 2M |
| Q1 2024 | 67 | 6M | 13.6% | 17 / 23 | 14 / 9 | 1M | 1M |
| Q4 2023 | 61 | 6M | 13.0% | 13 / 27 | 9 / 8 | 2M | 0M |
| Q3 2023 | 56 | 4M | 9.4% | 25 / 26 | 1 / 4 | 4M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GNLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,193,626 | 2.64% | $3.59M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 467,369 | 1.03% | $1.41M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 211,075 | 0.47% | $643.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 138,046 | 0.31% | $415.52K | 0.03% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 62,137 | 0.14% | $189.52K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 58,298 | 0.13% | $177.81K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 34,323 | 0.08% | $103.31K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 26,033 | 0.06% | $79.40K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 25,000 | 0.06% | $73.50K | 0.00% | Jul 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 16,729 | 0.04% | $50.35K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 9,299 | 0.02% | $27.99K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 4,629 | 0.01% | $13.61K | 0.00% | Jul 31, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 228 | 0.00% | $670 | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -300 | -0.00% | -$903 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yong Yu | Chief Scientific Officer | 258,688 | 0.57% | Sep 2, 2026 |
| Thomas Zindrick | President and CEO | 1,426,427 | 3.15% | Sep 2, 2026 |
| Joseph Cappello | Chief Technical Officer | 318,480 | 0.70% | Sep 2, 2026 |
| Eric Groen | General Counsel | 233,957 | 0.52% | Jun 18, 2026 |
| Matthew Pulisic | Chief Financial Officer | 278,906 | 0.62% | Jun 18, 2026 |
| Ralph Smalling | Head of Regulatory | 67,611 | 0.15% | Jun 4, 2026 |
| Jason Litten | Chief Medical Officer | – | – | Jan 7, 2026 |
| Sean Ryder | General Counsel | 47,621 | 0.11% | May 13, 2025 |
| Lourie S. Zak | Chief Financial Officer | 82,452 | 0.18% | Dec 20, 2024 |
| John W. Smither | Director | 91,403 | 0.20% | Jul 2, 2026 |
| Mary Mirabelli | Director | 102,693 | 0.23% | Jun 18, 2026 |
| John Thomas | Director | 501,193 | 1.11% | Jun 18, 2026 |
| James L. Tyree | Director | 96,483 | 0.21% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yong Yu Chief Scientific Officer | Aug 31, 2026 | Sale | −9,683 | $2.75 | $26.63K | 258,688 |
| Joseph Cappello Chief Technical Officer | Aug 31, 2026 | Sale | −10,257 | $2.74 | $28.10K | 318,480 |
| Thomas Zindrick President and CEO | Aug 31, 2026 | Sale | −34,463 | $2.67 | $92.02K | 1,226,427 |
| Yong Yu Chief Scientific Officer | Aug 4, 2026 | Sale | −653 | $2.94 | $1.92K | 268,371 |
| Joseph Cappello Chief Technical Officer | Aug 4, 2026 | Sale | −653 | $2.95 | $1.93K | 328,737 |
| Thomas Zindrick President and CEO | Aug 4, 2026 | Sale | −3,023 | $2.95 | $8.92K | 1,260,890 |
| John W. Smither Director | Jul 1, 2026 | Sale | −12,000 | $2.91 | $34.92K | 91,403 |
| Matthew Pulisic Chief Financial Officer | Jun 16, 2026 | Award | +278,906 | – | – | 278,906 |
| Thomas Zindrick President and CEO | Jun 16, 2026 | Award | +730,601 | – | – | 1,263,913 |
| Joseph Cappello Chief Technical Officer | Jun 16, 2026 | Award | +174,841 | – | – | 329,390 |
| James L. Tyree Director | Jun 16, 2026 | Award | +28,409 | – | – | 96,483 |
| Yong Yu Chief Scientific Officer | Jun 16, 2026 | Award | +119,318 | – | – | 269,024 |
| John Thomas Director | Jun 16, 2026 | Award | +28,409 | – | – | 501,193 |
| Eric Groen General Counsel | Jun 16, 2026 | Award | +233,957 | – | – | 233,957 |
| John W. Smither Director | Jun 16, 2026 | Award | +28,409 | – | – | 103,403 |
| Mary Mirabelli Director | Jun 16, 2026 | Award | +28,409 | – | – | 102,693 |
| Ralph Smalling Head of Regulatory | Jun 3, 2026 | Sale | −192 | $2.93 | $563 | 67,611 |
| John Thomas Director | Jun 1, 2026 | Sale(10b5-1 plan) | −10,000 | $2.98 | $29.80K | 472,784 |
| Joseph Cappello Chief Technical Officer | May 11, 2026 | Sale | −605 | $2.97 | $1.80K | 154,549 |
| Thomas Zindrick President and CEO | May 11, 2026 | Sale | −2,798 | $2.94 | $8.23K | 532,051 |
| Yong Yu Chief Scientific Officer | May 11, 2026 | Sale | −605 | $2.97 | $1.80K | 149,706 |
| Ralph Smalling Head of Regulatory | May 11, 2026 | Sale | −270 | $2.98 | $805 | 67,803 |
| Ralph Smalling Head of Regulatory | Mar 25, 2026 | Sale | −240 | $2.51 | $602 | 68,073 |
| Thomas Zindrick President and CEO | Mar 24, 2026 | Sale | −3,582 | $2.42 | $8.67K | 534,849 |
| Joseph Cappello Chief Technical Officer | Mar 24, 2026 | Sale | −906 | $2.42 | $2.19K | 155,154 |
| Yong Yu SVP, Clinical Development | Mar 24, 2026 | Sale | −906 | $2.42 | $2.19K | 144,938 |
| Ralph Smalling Head of Regulatory | Mar 24, 2026 | Sale | −345 | $2.42 | $835 | 68,313 |
| John Thomas Director | Mar 2, 2026 | Sale(10b5-1 plan) | −10,000 | $2.90 | $29.00K | 482,784 |
| Ralph Smalling Head of Regulatory | Dec 5, 2025 | Sale | −165 | $4.69 | $774 | 68,658 |
| John Thomas Director | Dec 1, 2025 | Sale(10b5-1 plan) | −10,000 | $5.00 | $50.00K | 492,784 |
| Thomas Zindrick President and CEO | Nov 17, 2025 | Sale | −4,509 | $5.37 | $24.21K | 538,431 |
| Joseph Cappello Chief Technical Officer | Nov 17, 2025 | Sale | −973 | $5.37 | $5.23K | 156,060 |
| Yong Yu SVP, Clinical Development | Nov 17, 2025 | Sale | −973 | $5.37 | $5.23K | 145,844 |
| Ralph Smalling Head of Regulatory | Nov 17, 2025 | Sale | −343 | $5.37 | $1.84K | 68,823 |
| Ralph Smalling Head of Regulatory | Sep 3, 2025 | Sale | −580 | $3.36 | $1.95K | 69,166 |
| Ralph Smalling Head of Regulatory | Sep 1, 2025 | Award | +10,000 | – | – | 70,990 |
| Ralph Smalling Head of Regulatory | Aug 27, 2025 | Award | +26,230 | – | – | 60,990 |
| Mary Mirabelli Director | Aug 27, 2025 | Award | +22,283 | – | – | 73,284 |
| John W. Smither Director | Aug 27, 2025 | Award | +22,283 | – | – | 74,994 |
| James L. Tyree Director | Aug 27, 2025 | Award | +22,283 | – | – | 68,074 |
| Thomas Zindrick President and CEO | Aug 27, 2025 | Award | +361,200 | – | – | 554,161 |
| Yong Yu SVP, Clinical Development | Aug 27, 2025 | Award | +101,480 | – | – | 150,036 |
| John Thomas Director | Aug 27, 2025 | Award | +22,283 | – | – | 502,784 |
| Joseph Cappello Chief Technical Officer | Aug 27, 2025 | Award | +107,500 | – | – | 159,766 |
| Thomas Zindrick President and CEO | Aug 21, 2025 | Sale | −12,673 | $3.33 | $42.20K | 542,940 |
| Joseph Cappello Chief Technical Officer | Aug 21, 2025 | Sale | −1,463 | $3.36 | $4.92K | 157,033 |
| Joseph Cappello Chief Technical Officer | Aug 21, 2025 | Sale | −1,270 | $3.33 | $4.23K | 158,496 |
| Yong Yu SVP, Clinical Development | Aug 21, 2025 | Sale | −3,219 | $3.36 | $10.82K | 146,817 |
| Ralph Smalling Head of Regulatory | Aug 21, 2025 | Sale | −1,244 | $3.36 | $4.18K | 69,746 |
| John Thomas Director | Jun 6, 2025 | Gift | −25,000 | – | – | 480,501 |
| Yong Yu VP, Clinical Trial Operations | May 12, 2025 | Sale | −5,579 | $2.92 | $16.29K | 47,640 |
| Thomas Zindrick President and CEO, Director | May 12, 2025 | Sale | −10,764 | $2.92 | $31.43K | 191,447 |
| Ralph Smalling Head of Regulatory | May 12, 2025 | Sale | −1,259 | $2.92 | $3.68K | 34,760 |
| Sean Ryder General Counsel | May 12, 2025 | Sale | −4,475 | $2.92 | $13.07K | 47,621 |
| Joseph Cappello VP, Pharmaceutical Development | May 12, 2025 | Sale | −4,737 | $2.92 | $13.83K | 52,266 |
| Joseph Cappello VP, Pharmaceutical Development | Mar 14, 2025 | Award | +13,350 | – | – | 57,003 |
| Yong Yu VP, Clinical Trial Operations | Mar 14, 2025 | Award | +13,350 | – | – | 53,219 |
| Thomas Zindrick President and CEO, Director | Mar 14, 2025 | Award | +30,339 | – | – | 202,211 |
| Sean Ryder General Counsel | Mar 14, 2025 | Award | +10,708 | – | – | 52,096 |
| Ralph Smalling Head of Regulatory | Mar 14, 2025 | Award | +4,172 | – | – | 36,019 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Smither John Director | Jul 1, 2026 | 12,000 | $34.90K | Jul 1, 2026 | Restricted Stock |
| Thomas Johnny Officer | Jun 1, 2026 | 10,000 | $30.50K | Jun 1, 2026 | Founders Shares |
| Thomas Johnny Officer | Mar 2, 2026 | 10,000 | $29.80K | Mar 2, 2026 | Founders Shares |
| Thomas Johnny Director | Dec 1, 2025 | 10,000 | $55.60K | Dec 1, 2025 | Founders Shares |
| L. Tyree James Director | Dec 30, 2024 | 3,460 | $8.51K | Dec 30, 2024 | Restricted stock vesting under a registered plan |
| L. Tyree James Director | Sep 11, 2024 | 1,730 | $4.34K | Sep 11, 2024 | Restricted Stock Units |
| 2010 Retained Annuity Trust Szalay 10% Stockholder | Sep 6, 2024 | 140,000 | $392.00K | Sep 9, 2024 | Irrevocable Grant |
| 2010 Retained Annuity Trust Szalay 10% Stockholder | Aug 22, 2024 | 400,000 | $872.00K | Aug 23, 2024 | Irrevocable Grant |
| 2010 Retained Annuity Trust Szalay 10% Stockholder | Apr 15, 2024 | 494,744 | $2.10M | Apr 15, 2024 | Irrevocable Grant |
| 2010 Retained Annuity Trust Szalay 10% Stockholder | Apr 11, 2024 | 494,744 | $2.10M | Apr 15, 2024 | Private Placement |
| Yu Yong Officer | Dec 15, 2023 | 32,535 | $428.18K | Dec 15, 2023 | Restricted stock vesting under a registered plan |
| Thomas Johnny Director | Dec 13, 2023 | 9,000 | $120.39K | Dec 13, 2023 | Restricted stock vesting under a registered plan |
| L. Tyree James Officer | Dec 13, 2023 | 9,000 | $118.97K | Dec 13, 2023 | Restricted stock vesting under a registered plan |
| Yu Yong Officer | Dec 7, 2023 | 36,800 | $436.00K | Dec 7, 2023 | Restricted stock vesting under a registered plan |
| Yong Yu Officer | Nov 17, 2023 | 36,800 | $479.14K | Nov 17, 2023 | Restricted stock vesting under a registered plan |